您当前的位置：

Ximelagatran

(Synonyms: H 376/95)

目录号: PL01633 纯度: ≥98%

Ximelagatran (H 376/95) 是一种口服活性凝血酶抑制剂，可选择性和竞争性地抑制游离和凝块结合的凝血酶。Ximelagatran 还是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。

CAS No. :192939-46-1

商品编号	规格	价格	会员价
PL01633-500μg	500μg	¥258.00	请登录
PL01633-1mg	1mg	¥366.00	请登录
PL01633-5mg	5mg	¥733.00	请登录
PL01633-10mg	10mg	¥1285.00	请登录
PL01633-25mg	25mg	¥2225.00	请登录
PL01633-50mg	50mg	¥2975.00	请登录
PL01633-100mg	100mg	¥3925.00	请登录
PL01633-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3359.00	请登录
PL01633-1 mL x 10 mM (in DMSO)		¥768.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Ximelagatran
中文别名	希美加群;Ximelagatran 抑制剂;三环己基膦[1,3-双(2,4,6-三甲基苯基)-4,5-二氢咪唑-2-亚基][(苯硫基)亚甲基]钌(II)二氯
英文名称	Ximelagatran
英文别名	Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-,ethyl ester;EXANTA;ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate;Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]ca...;Glycine,N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethy;Ximelagatran;Ximelagatran;[14C]-Ximelagatran;[3H]-Ximelagatran;Exanta (TN);Exarta;H 376;USAN;ximelagatra;Ximelagatran [USAN:INN];N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-glycine ethyl ester;N-[(1R)-1-Cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]glycine ethyl ester;XIMELEGATRAN;Exanta (XiMelagatran);Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ximelagatran;Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxoethyl]Amino]Acetate Ethyl 2-[[(1R)-1-Cyclohexyl-2-[(2S)-2-[[4-(N'-Hydroxycarbamimidoyl)Phenyl]Methylcarbamoyl]Azetidin-1-Yl]-2-Oxo-Ethyl
Cas No.	192939-46-1
分子式	C₂₄H₃₅N₅O₅
分子量	473.57
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	Ximelagatran (H 376/95) 是一种口服活性凝血酶抑制剂，可选择性和竞争性地抑制游离和凝块结合的凝血酶。Ximelagatran 还是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。

产品详情	Ximelagatran (H 376/95) 是一种口服活性凝血酶抑制剂，可选择性和竞争性地抑制游离和凝块结合的凝血酶。Ximelagatran 还是一种抗凝药物，具有快速起效的抗凝作用，可预测的，剂量依赖性的药代动力学和药效学。
生物活性	Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
性状	Solid
体外研究(In Vitro)	Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30. [2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059.

溶解度数据	In Vitro: DMSO : 250 mg/mL (527.91 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30.
[2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Ximelagatran

相关产品

The molarity calculator equation

The dilution calculator equation